Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.

Authors

Brett King
Catherine Maari
Edward Lain
Jonathan I. Silverberg, George Washington University
Maher Issa
Katrin Holzwarth
Dennis Brinker
Tracy Cardillo
Fabio P Nunes
Eric L Simpson

Document Type

Journal Article

Publication Date

5-1-2021

Journal

American Journal of Clinical Dermatology

Volume

22

Issue

3

Inclusive Pages

395-405

DOI

10.1007/s40257-021-00602-x

Comments

Epub 2021 Apr 7

APA Citation

King, B., Maari, C., Lain, E., Silverberg, J. I., Issa, M., Holzwarth, K., Brinker, D., Cardillo, T., Nunes, F., & Simpson, E. (2021). Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.. American Journal of Clinical Dermatology, 22 (3). http://dx.doi.org/10.1007/s40257-021-00602-x

Peer Reviewed

1